Pacific Biosciences Of California (PACB) Non Operating Interest Expenses (2012 - 2026)

Pacific Biosciences Of California has reported Non Operating Interest Expenses for 15 years, with the latest figure at $2.1 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 21.4% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $7.3 million, a 24.98% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 48.15% from the prior year.
• Non Operating Interest Expenses was $2.1 million for Q2 2026 at Pacific Biosciences Of California, up from $1.7 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $3.7 million in Q1 2022, with the low at $1.7 million in Q1 2025.
• Average Non Operating Interest Expenses over 5 years is $3.0 million, with a median of $3.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Non Operating Interest Expenses jumped 106.65% in 2022, then slumped 51.41% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $3.6 million in 2022, then decreased by 2.11% to $3.6 million in 2023, then decreased by 22.79% to $2.8 million in 2024, then sank by 36.89% to $1.7 million in 2025, then rose by 21.26% to $2.1 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.1 million (Q2 2026), $1.7 million (Q1 2026), and $1.7 million (Q4 2025), per Business Quant data.